Kodiak Sciences Inc. (KOD) Announces Clinical Trial Update
Kodiak Sciences Inc. (KOD) provided an update on its clinical development programs.
Clinical Development Highlights:
- Phase 3 trial ongoing
- Data expected in 2022
No specific business highlights were provided.
Upcoming Milestones:
- targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are progressing the bioconjugate cGMP manufacturing, non-clinical toxicology and other supporting activities towards expected IND submission in 2H 2022
- targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
- expected in June 2022
Kodiak Sciences Inc. (KOD) Announces Clinical Trial Update Kodiak Sciences Inc. (KOD) provided an update on its clinical development programs. Clinical Development Highlights: - Phase 3 trial ongoing - Data expected in 2022 No specific business highlights were provided. Upcoming Milestones: - targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are progressing the bioconjugate cGMP manufacturing, non-clinical toxicology and other supporting activities towards expected IND submission in 2H 2022 - targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 - expected in June 2022